Our approach
We address unmet needs in immuno-oncology, CNS and rare diseases using the following strategies:
→ Identifying and validating new therapeutic GPCR targets
→ Designing allosteric modulators presenting better efficacy
→ Selecting biased ligands presenting better safety profile
→ Addressing orphan and historically intractable GPCRs
→ Increasing the success rate of High Throughput Screening (HTS) campaigns
Our recent communications
Learn about last developments of our oncology/immuno-oncology franchise presented at the 2020 AACR Virtual Annual Meeting II
→ DT095895, a selective EP4 receptor antagonist with monotherapy efficacy in syngeneic mouse model(s) and best in class properties (Poster #6697) presents the complete characterization of Domain drug candidate benchmarked to EP4 antagonist molecules currently in the clinic and demonstrating a best-in-class potential.
See the poster
→ GPCR-ome modulation upon PD1/PDL1 axis blockade (Poster #934), co-authored with Explicyte, Bordeaux, France and Institut Bergonié, Bordeaux, France, discloses an in-depth GPCR expression analysis from tumor microenvironment to dissect out mechanisms of resistance to immune checkpoint inhibitors. Such data open avenues for the discovery of the next generation of immune checkpoints.
See the poster
→ Decrypting EGFR signalling with BRET biosensors: a novel approach to study RTK mutations and the effects of inhibitors (Poster #6304) illustrates a valuable BRET-based platform used to characterize RTK candidates regarding constitutive activity, real-time kinetics or impact of RTK mutations on signalling pathways.
See the poster
→ Development of a pharmacological platform to study in real time immune checkpoints signaling pathways: validation with therapeutics mAbs and small molecules (Poster #6308) presents the last generation of bioSens-All™ platform dedicated to the identification and characterization of immune checkpoint inhibitors.
See the poster